A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer

Nuclear Medicine and Biology

Volumn 38, Issue 1, 2011, Pages 129-136

  Scollard, Deborah A ^a   Chan, Conrad ^a   Holloway, Claire M B ^b   Reilly, Raymond M ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

111In; Breast cancer; Good manufacturing practices (GMP); Imaging; Kit; Radioimmunoguided surgery (RIGS); Trastuzumab Fab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; PAPAIN; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; TRASTUZUMAB PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY; PENTETIC ACID;

ARTICLE; BREAST CANCER; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG PURITY; DRUG STERILITY; ENZYME IMMOBILIZATION; GOOD MANUFACTURING PRACTICE; IMMUNOREACTIVITY; INCUBATION TIME; LIGAND BINDING; PH; RADIOACTIVITY; RADIOCHEMISTRY; RADIOIMMUNOLOGY; ROOM TEMPERATURE; ULTRAFILTRATION; BREAST TUMOR; CHEMISTRY; COMPUTER ASSISTED SURGERY; HUMAN; INJECTION; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; PATHOLOGY; QUALITY CONTROL; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INDIUM RADIOISOTOPES; INJECTIONS; MOLECULAR IMAGING; PENTETIC ACID; QUALITY CONTROL; RECEPTOR, ERBB-2; SURGERY, COMPUTER-ASSISTED;

EID: 78650995184     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.06.010     Document Type: Article

References (26)

1. Revillion F., Bonneterre J., Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998, 34:791-808.
2. Allred D.C., Clark G.M., Molina R., Tandon A.K., Schnitt S.J., Gilchrist K.W., et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23:974-979.
3. Pegram M.D., Pauletti G., Slamon D.J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998, 52:65-77.
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
5. McLarty K., Reilly R.M. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin Pharmacol Ther 2007, 81:420-424.
6. Reilly R.M. Aiming for a direct hit: combining molecular imaging with targeted cancer therapy. J Nucl Med 2009, 50:1017-1019.
7. Badellino F., Bertoglio S., Mariani G., Meszaros P., Canavese G., Percivale P. Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer. Semin Surg Oncol 1998, 15:245-248.
8. Percivale P., Bertoglio S., Meszaros P., Canavese G., Cafiero F., Gipponi M., et al. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. J Clin Oncol 1996, 14:1599-1603.
9. Behr T.M., Béhé M., Wörmann B. Trastuzumab and breast cancer. N Engl J Med 2001, 345:995-996.
10. McLarty K., Cornelissen B., Cai Z., Scollard D., Costantini D., Done S.J., et al. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing human breast cancer xenografts. J Nucl Med 2009, 50:1340-1348.
11. McLarty K., Cornelissen B., Scollard D.A., Done S.J., Chun K., Reilly R.M. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009, 36:81-93.
12. Perik P.J., Lub-de Hooge M.N., Gietema J.A., van der Graaf W.T.A., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
13. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER-2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:704-706.
14. Tang Y., Wang J., Scollard D.A., Mondal H., Holloway C., Kahn H.J., et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005, 32:51-58.
15. Tang Y., Scollard D., Chen P., Wang J., Holloway C., Reilly R.M. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005, 26:427-432.
16. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., et al. Increased affinity leads to improved selective tumour delivery of single-chain Fv antibodies. Cancer Res 1998, 58:485-490.
17. Robinson M.K., Doss M., Shaller C., Narayanan D., Marks J.D., Adler L.P., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005, 65:1471-1478.
18. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005, 65:5907-5916.
19. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Design 2008, 14:2999-3019.
20. Kramer-Marek G., Kiesewetter D.O., Capala J. HER2 expression changes in breast cancer xenografts following therapeutic intervention can be quantified using PET imaging and 18F-labeled affibody molecules. J Nucl Med 2009, 50:1131-1139.
21. Orlova A., Wållberg H., Stone-Elander S., Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
22. Reilly R.M., Sandhu J., Alvarez-Diez T.M., Gallinger S., Kirsh J., Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995, 28:126-142.
23. Reilly R.M., Scollard D.A., Wang J., Mondal H., Chen P., Henderson L.A., et al. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. J Nucl Med 2004, 45:701-708.
24. Anonymous Octreoscan Kit for the preparation of indium-111 pentetreotide 1995, Mallinckrodt Medical Inc, St. Louis (Mo).
25. Anonymous Questions and answers about FDA's enforcement action regarding unapproved topical drug products containing papain Accessed January 9, 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm119646.htm.
26. Reilly R.M. The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. Handbook of Biopharmaceutical Technology 2007, 987-1053. John Wiley & Sons, Toronto. S.C. Gad (Ed.).